Q-omics provides the consensus-scored ZBTB8OS profile across patient tissues and cancer cell-line models. ZBTB8OS expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, ZBTB8OS is differentially expressed in 12, with the highest sampling consensus in HNSC. Additionally, ZBTB8OS RNA expression shows 19,005 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight KIRC, HNSC, and UVM as cancer lineages where ZBTB8OS shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ZBTB8OS — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ZBTB8OS survival associations across molecular data types. ZBTB8OS RNA expression shows survival associations in the most cancer types (24), followed by mutation status (2) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ZBTB8OS RNA expression–survival associations across cancer types. High ZBTB8OS expression shows unfavorable associations in KIRC, ACC, KICH, LIHC, UVM and LGG. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for ZBTB8OS RNA expression.
This table summarizes ZBTB8OS tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 5. The strongest signals are observed in KIRC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for ZBTB8OS. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ZBTB8OS shows lower tumor expression in KICH and higher tumor expression in HNSC, KIRC, LIHC, STAD and BLCA. The HNSC box plot shows higher ZBTB8OS RNA expression in tumor versus normal tissue (log2 FC = +0.611, t-test p < 0.001).
This table shows molecular features associated with ZBTB8OS in patient tissues and cancer cell lines. In patient samples, ZBTB8OS shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, ZBTB8OS RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OVARY, while CRISPR and shRNA rows add functional-dependency signals in UPPER_AERODIGESTIVE_TRACT and BLOOD_Lymphoma.
